Kite Pharma (KITE) CMO Chang Says R&D Pipeline 'Well Balanced' Between Blood, Solid Tumors - Investor Day

October 18, 2016 12:50 PM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Kite Pharma (NASDAQ: KITE) chief medical officer, David D. Chang, M.D., Ph.D., said today that the company's R&D pipeline is "well balanced" between blood and solid tumors. Chang was speaking at Kite's Investor Day today.

Chang also introduced hour new preclinical programs. Kite will filed IND for KITE-796 in 2018, for KITE-585 in 2017, for KITE-718 in 2016, and KITE-439 in 2018.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Management Comments, Trader Talk

Add Your Comment